How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Buy
68
GALDY Quote, Financials, Valuation and Earnings
Last price:
$37.27
Seasonality move
:
-23.42%
Day range:
$37.53 - $38.30
52-week range:
$17.27 - $42.93
Dividend yield:
0.04%
P/E ratio:
130.29x
P/S ratio:
9.57x
P/B ratio:
4.98x
Volume:
59.6K
Avg. volume:
140.9K
1-year change:
52.32%
Market cap:
$44.3B
Revenue:
$4.4B
EPS (TTM):
$0.32
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GALDY
Galderma Group AG
|
-- | -- | -- | -- | -- |
|
ACIU
AC Immune SA
|
$1.5M | -$0.22 | 18.61% | -6.92% | $9.21 |
|
ADXN
Addex Therapeutics Ltd.
|
$242.8K | -- | 2.35% | -- | $30.00 |
|
CRSP
CRISPR Therapeutics AG
|
$3.9M | -$1.23 | -89.16% | -180.98% | $84.39 |
|
ONC
BeOne Medicines Ltd.
|
$1.5B | $1.44 | 25.24% | 4402.9% | $404.19 |
|
RHHBY
Roche Holding AG
|
$19.8B | -- | -- | -- | $56.66 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GALDY
Galderma Group AG
|
$37.73 | -- | $44.3B | 130.29x | $0.03 | 0.04% | 9.57x |
|
ACIU
AC Immune SA
|
$3.27 | $9.21 | $329M | -- | $0.00 | 0% | 63.77x |
|
ADXN
Addex Therapeutics Ltd.
|
$7.66 | $30.00 | $9.4M | 0.77x | $0.00 | 0% | 35.04x |
|
CRSP
CRISPR Therapeutics AG
|
$51.31 | $84.39 | $4.9B | -- | $0.00 | 0% | 117.04x |
|
ONC
BeOne Medicines Ltd.
|
$345.00 | $404.19 | $38.2B | 663.72x | $0.00 | 0% | 7.71x |
|
RHHBY
Roche Holding AG
|
$57.12 | $56.66 | $363.9B | 42.69x | $1.39 | 2.43% | 4.95x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GALDY
Galderma Group AG
|
26.02% | 1.432 | -- | 0.80x |
|
ACIU
AC Immune SA
|
6.95% | 3.733 | 2.01% | 1.10x |
|
ADXN
Addex Therapeutics Ltd.
|
0.61% | 1.645 | 0.5% | 1.91x |
|
CRSP
CRISPR Therapeutics AG
|
9.92% | 2.738 | 3.47% | 16.13x |
|
ONC
BeOne Medicines Ltd.
|
31.57% | -0.304 | 5.05% | 2.09x |
|
RHHBY
Roche Holding AG
|
53.53% | -0.511 | -- | 0.88x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GALDY
Galderma Group AG
|
-- | -- | 3.62% | 4.9% | -- | -- |
|
ACIU
AC Immune SA
|
-- | -$19.6M | -72.31% | -75.88% | -1671.93% | -$24.4M |
|
ADXN
Addex Therapeutics Ltd.
|
-- | -$869.9K | -73.49% | -73.84% | -1403.07% | -$687.4K |
|
CRSP
CRISPR Therapeutics AG
|
-$60.6M | -$132.1M | -23.42% | -26.17% | -14854.78% | -$84.7M |
|
ONC
BeOne Medicines Ltd.
|
$1.2B | $163.3M | 1.43% | 1.92% | 11.55% | $355.1M |
|
RHHBY
Roche Holding AG
|
-- | -- | 14.32% | 28.65% | -- | -- |
Galderma Group AG vs. Competitors
-
Which has Higher Returns GALDY or ACIU?
AC Immune SA has a net margin of -- compared to Galderma Group AG's net margin of -1688.87%. Galderma Group AG's return on equity of 4.9% beat AC Immune SA's return on equity of -75.88%.
Company Gross Margin Earnings Per Share Invested Capital GALDYGalderma Group AG-- -- $10.4B ACIUAC Immune SA-- -$0.20 $84.3M -
What do Analysts Say About GALDY or ACIU?
Galderma Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand AC Immune SA has an analysts' consensus of $9.21 which suggests that it could grow by 181.86%. Given that AC Immune SA has higher upside potential than Galderma Group AG, analysts believe AC Immune SA is more attractive than Galderma Group AG.
Company Buy Ratings Hold Ratings Sell Ratings GALDYGalderma Group AG0 0 0 ACIUAC Immune SA4 0 0 -
Is GALDY or ACIU More Risky?
Galderma Group AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AC Immune SA has a beta of 1.660, suggesting its more volatile than the S&P 500 by 66.038%.
-
Which is a Better Dividend Stock GALDY or ACIU?
Galderma Group AG has a quarterly dividend of $0.03 per share corresponding to a yield of 0.04%. AC Immune SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galderma Group AG pays -- of its earnings as a dividend. AC Immune SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GALDY or ACIU?
Galderma Group AG quarterly revenues are --, which are smaller than AC Immune SA quarterly revenues of $1.2M. Galderma Group AG's net income of -- is lower than AC Immune SA's net income of -$19.8M. Notably, Galderma Group AG's price-to-earnings ratio is 130.29x while AC Immune SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galderma Group AG is 9.57x versus 63.77x for AC Immune SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GALDYGalderma Group AG9.57x 130.29x -- -- ACIUAC Immune SA63.77x -- $1.2M -$19.8M
-
Which has Higher Returns GALDY or ADXN?
Addex Therapeutics Ltd. has a net margin of -- compared to Galderma Group AG's net margin of -3178.71%. Galderma Group AG's return on equity of 4.9% beat Addex Therapeutics Ltd.'s return on equity of -73.84%.
Company Gross Margin Earnings Per Share Invested Capital GALDYGalderma Group AG-- -- $10.4B ADXNAddex Therapeutics Ltd.-- -$2.10 $7.5M -
What do Analysts Say About GALDY or ADXN?
Galderma Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Addex Therapeutics Ltd. has an analysts' consensus of $30.00 which suggests that it could grow by 291.65%. Given that Addex Therapeutics Ltd. has higher upside potential than Galderma Group AG, analysts believe Addex Therapeutics Ltd. is more attractive than Galderma Group AG.
Company Buy Ratings Hold Ratings Sell Ratings GALDYGalderma Group AG0 0 0 ADXNAddex Therapeutics Ltd.0 0 0 -
Is GALDY or ADXN More Risky?
Galderma Group AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Addex Therapeutics Ltd. has a beta of 1.459, suggesting its more volatile than the S&P 500 by 45.904%.
-
Which is a Better Dividend Stock GALDY or ADXN?
Galderma Group AG has a quarterly dividend of $0.03 per share corresponding to a yield of 0.04%. Addex Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galderma Group AG pays -- of its earnings as a dividend. Addex Therapeutics Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GALDY or ADXN?
Galderma Group AG quarterly revenues are --, which are smaller than Addex Therapeutics Ltd. quarterly revenues of $62K. Galderma Group AG's net income of -- is lower than Addex Therapeutics Ltd.'s net income of -$2M. Notably, Galderma Group AG's price-to-earnings ratio is 130.29x while Addex Therapeutics Ltd.'s PE ratio is 0.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galderma Group AG is 9.57x versus 35.04x for Addex Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GALDYGalderma Group AG9.57x 130.29x -- -- ADXNAddex Therapeutics Ltd.35.04x 0.77x $62K -$2M
-
Which has Higher Returns GALDY or CRSP?
CRISPR Therapeutics AG has a net margin of -- compared to Galderma Group AG's net margin of -11973.12%. Galderma Group AG's return on equity of 4.9% beat CRISPR Therapeutics AG's return on equity of -26.17%.
Company Gross Margin Earnings Per Share Invested Capital GALDYGalderma Group AG-- -- $10.4B CRSPCRISPR Therapeutics AG-6819.57% -$1.17 $2.1B -
What do Analysts Say About GALDY or CRSP?
Galderma Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $84.39 which suggests that it could grow by 64.47%. Given that CRISPR Therapeutics AG has higher upside potential than Galderma Group AG, analysts believe CRISPR Therapeutics AG is more attractive than Galderma Group AG.
Company Buy Ratings Hold Ratings Sell Ratings GALDYGalderma Group AG0 0 0 CRSPCRISPR Therapeutics AG12 9 1 -
Is GALDY or CRSP More Risky?
Galderma Group AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.724, suggesting its more volatile than the S&P 500 by 72.403%.
-
Which is a Better Dividend Stock GALDY or CRSP?
Galderma Group AG has a quarterly dividend of $0.03 per share corresponding to a yield of 0.04%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galderma Group AG pays -- of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GALDY or CRSP?
Galderma Group AG quarterly revenues are --, which are smaller than CRISPR Therapeutics AG quarterly revenues of $889K. Galderma Group AG's net income of -- is lower than CRISPR Therapeutics AG's net income of -$106.4M. Notably, Galderma Group AG's price-to-earnings ratio is 130.29x while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galderma Group AG is 9.57x versus 117.04x for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GALDYGalderma Group AG9.57x 130.29x -- -- CRSPCRISPR Therapeutics AG117.04x -- $889K -$106.4M
-
Which has Higher Returns GALDY or ONC?
BeOne Medicines Ltd. has a net margin of -- compared to Galderma Group AG's net margin of 8.84%. Galderma Group AG's return on equity of 4.9% beat BeOne Medicines Ltd.'s return on equity of 1.92%.
Company Gross Margin Earnings Per Share Invested Capital GALDYGalderma Group AG-- -- $10.4B ONCBeOne Medicines Ltd.83.86% $1.09 $6B -
What do Analysts Say About GALDY or ONC?
Galderma Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand BeOne Medicines Ltd. has an analysts' consensus of $404.19 which suggests that it could grow by 17.16%. Given that BeOne Medicines Ltd. has higher upside potential than Galderma Group AG, analysts believe BeOne Medicines Ltd. is more attractive than Galderma Group AG.
Company Buy Ratings Hold Ratings Sell Ratings GALDYGalderma Group AG0 0 0 ONCBeOne Medicines Ltd.19 0 1 -
Is GALDY or ONC More Risky?
Galderma Group AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BeOne Medicines Ltd. has a beta of 0.518, suggesting its less volatile than the S&P 500 by 48.23%.
-
Which is a Better Dividend Stock GALDY or ONC?
Galderma Group AG has a quarterly dividend of $0.03 per share corresponding to a yield of 0.04%. BeOne Medicines Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galderma Group AG pays -- of its earnings as a dividend. BeOne Medicines Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GALDY or ONC?
Galderma Group AG quarterly revenues are --, which are smaller than BeOne Medicines Ltd. quarterly revenues of $1.4B. Galderma Group AG's net income of -- is lower than BeOne Medicines Ltd.'s net income of $125M. Notably, Galderma Group AG's price-to-earnings ratio is 130.29x while BeOne Medicines Ltd.'s PE ratio is 663.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galderma Group AG is 9.57x versus 7.71x for BeOne Medicines Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GALDYGalderma Group AG9.57x 130.29x -- -- ONCBeOne Medicines Ltd.7.71x 663.72x $1.4B $125M
-
Which has Higher Returns GALDY or RHHBY?
Roche Holding AG has a net margin of -- compared to Galderma Group AG's net margin of --. Galderma Group AG's return on equity of 4.9% beat Roche Holding AG's return on equity of 28.65%.
Company Gross Margin Earnings Per Share Invested Capital GALDYGalderma Group AG-- -- $10.4B RHHBYRoche Holding AG-- -- $82.8B -
What do Analysts Say About GALDY or RHHBY?
Galderma Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Roche Holding AG has an analysts' consensus of $56.66 which suggests that it could fall by -0.81%. Given that Roche Holding AG has higher upside potential than Galderma Group AG, analysts believe Roche Holding AG is more attractive than Galderma Group AG.
Company Buy Ratings Hold Ratings Sell Ratings GALDYGalderma Group AG0 0 0 RHHBYRoche Holding AG2 4 1 -
Is GALDY or RHHBY More Risky?
Galderma Group AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Roche Holding AG has a beta of 0.440, suggesting its less volatile than the S&P 500 by 56.044%.
-
Which is a Better Dividend Stock GALDY or RHHBY?
Galderma Group AG has a quarterly dividend of $0.03 per share corresponding to a yield of 0.04%. Roche Holding AG offers a yield of 2.43% to investors and pays a quarterly dividend of $1.39 per share. Galderma Group AG pays -- of its earnings as a dividend. Roche Holding AG pays out 58.07% of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios GALDY or RHHBY?
Galderma Group AG quarterly revenues are --, which are smaller than Roche Holding AG quarterly revenues of --. Galderma Group AG's net income of -- is lower than Roche Holding AG's net income of --. Notably, Galderma Group AG's price-to-earnings ratio is 130.29x while Roche Holding AG's PE ratio is 42.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galderma Group AG is 9.57x versus 4.95x for Roche Holding AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GALDYGalderma Group AG9.57x 130.29x -- -- RHHBYRoche Holding AG4.95x 42.69x -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 43x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 43x
Alerts
Sell
49
HYMC alert for Feb 3
Hycroft Mining Holding Corp. [HYMC] is up 19.68% over the past day.
Buy
67
FBRX alert for Feb 3
Forte Biosciences, Inc. [FBRX] is down 0.2% over the past day.
Buy
72
BNR alert for Feb 3
Burning Rock Biotech Ltd. [BNR] is down 15.43% over the past day.
